Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and ...

Lilly claims the single-dose versions cost at least 50% less than the list price of other incretin ... versions of Novo Nordisk's GLP-1 agonist drug semaglutide, sold as Wegovy for obesity ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain investment potential to beef up your portfolio.

Tirzepatide has been on the shortage list since 2022 ... of legal cases involving compounded weight-loss drugs, with Novo Nordisk and Lilly both filing lawsuits seeking to block the activity ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...